Drug intelligence / Profile preview

RGL-2102

Development stage: Unknown
Lead developer: Regenelead Therapies
Administration: Topical, Intramuscular

Overview

RGL-2102 is an investigational drug developed by Shanghai Regenelead Therapies for the treatment of chronic wounds and severe lower limb ischemia. It is being evaluated in both topical and injectable formulations, with clinical trials focusing on its safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy. The exact mechanism of action has not been disclosed publicly. Clinical development includes Phase 1 and Phase 2 studies in China for chronic wounds (topical administration) and severe lower limb ischemia (intramuscular injection)[1][2][3].

Beyond the preview

Go deeper on RGL-2102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGL-2102.

Explore the full profile